Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
about
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Efficacy and safety of daclata ...... a Phase III, open-label study.
@en
type
label
Efficacy and safety of daclata ...... a Phase III, open-label study.
@en
prefLabel
Efficacy and safety of daclata ...... a Phase III, open-label study.
@en
P2093
P2860
P50
P1476
Efficacy and safety of daclata ...... a Phase III, open-label study.
@en
P2093
Adrian Gadano
Christophe Moreno
Dennis Hernandez
Douglas Dieterich
Eric Hughes
Federico Pulido
Fiona McPhee
Gail Matthews
Hugo Cheinquer
Jean-Michel Molina
P2860
P2888
P304
P356
10.1007/S12072-017-9788-Z
P577
2017-02-16T00:00:00Z